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Objectives: To evaluate the inﬂuence of imatinib interruption and prior hydroxyurea use on the
outcome of patients with chronic myeloid leukemia.
Materials and methods: Between January 2010 and November 2013, patients with chronic phase
who received imatinib at the Kasr Al-ainy Center of Clinical Oncology were included.
Results: Sixty patients were included in this study, thirty three patients (55%) received imatinib
upfront, while 27 (45%) received imatinib post hydroxyurea. Imatinib was not given regularly in
50% of patients. In terms of response, only major molecular response and complete molecular
response were statistically signiﬁcant in favor of patients who were receiving imatinib regularly
compared to those who had interruption (p< 0.001, p< 0.001, respectively) , while there was
no difference in patients stratiﬁed according to prior hydroxyurea. The median progression free sur-
vival was 30.3 months (95% CI 24.3–36.3). Among the group of patients who received imatinib
regularly, progression free survival was longer (p= 0.049), there was no difference between those
who received prior hydroxyurea versus those who did not (p= 0.67).
Conclusion: Duration of prior hydroxyurea had no impact on response or progression free sur-
vival, while patients regular on imatinib had statistically signiﬁcant difference with respect to major
70 W.A. Edesa, R.R. Abdel-malekmolecular response, complete molecular response and progression free survival compared to those
who had periods of drug interruption, thus we need more governmental support to supply the drug
without interruption to improve the outcome of therapy.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic myeloid leukemia (CML) accounts for approximately
15 to 20 percent of leukemias in adults [1]. It has an annual
incidence of 1 to 2 cases per 100,000, with a slight male pre-
dominance [2–4].
CML is a myeloproliferative neoplasm characterized by the
BCR-ABL1 fusion gene located in the Philadelphia
chromosome (Ph+), and uncontrolled proliferation of mature
and maturing granulocytes with fairly normal differentiation
[5].
The management of Ph+, BCR-ABL1 + CML has under-
gone a profound evolution over a relatively short period of
time, starting with allogeneic stem cell transplantation and
recombinant Interferon-alfa, and more recently and most sig-
niﬁcantly, with the tyrosine kinase inhibitors (TKIs) [6–8].
The ﬁrst trials of TKIs in BCR-ABL-positive disease evalu-
ated imatinib in patients refractory or intolerant to interferon
therapy, which had been the standard of care prior to the
availability of imatinib. Subsequently, the randomized IRIS
trial (International Randomized Study of Interferon and
STI571) compared imatinib to interferon therapy in previously
untreated patients in chronic phase [9]. Imatinib produced sig-
niﬁcantly higher hematologic and cytogenetic response rates
with deeper, more durable responses, and much less toxicity.
No survival beneﬁt has been demonstrated due to the large
number of patients allowed to switch from Interferon to ima-
tinib. However, several historical/retrospective comparisons
have shown signiﬁcantly better overall survival following treat-
ment with imatinib than with interferon-containing regimens
[10,11]. Thus, imatinib was the ﬁrst approved TKI in the man-
agement of CML.
Here, we retrospectively reviewed patients referred to the
Kasr Al-ainy Center of Clinical Oncology and Nuclear
Medicine (NEMROCK) with the diagnosis of chronic phase
CML and treated with imatinib aiming at evaluation of the
inﬂuence of imatinib interruption and prior hydroxyurea use
on the response and progression free survival.
Patients and methods
Between January 2010 and December 2013, all patients with
chronic phase CML who received imatinib at NEMROCK
were included in a retrospective analysis. All patients started
on imatinib 400 mg daily. Patients were assessed every 2 weeks
in the ﬁrst 2 months then on monthly basis.
The patients were analyzed with respect to the demographic
proﬁle, European Treatment and Outcome Study (EUTOS)
scoring system for CML, molecular response, safety and sur-
vival. Cytogenetic analysis was not performed routinely in
our institution. A baseline qualitative PCR test was done to
conﬁrm the type of BCR-ABL transcripts. Molecular responsewas performed using real time quantitative polymerase chain
reaction (RT Q-PCR) every 3 months.
Complete hematological response (CHR) was deﬁned as
white blood cell count <10 · 109/L, platelet count
<450 · 109/L, presence of <5% myelocytes plus metamyelo-
cytes, <20% basophils and absence of blasts or promyelocytes
in the peripheral blood, or extramedullary involvement. Major
molecular response (MMR) was deﬁned as BCR-ABL:
ABL 6 0.1%, while complete molecular response (CMR) or
molecularly undetectable leukemia refers to no detectable
BCR-ABL transcripts by RTQ-PCR.
The 2009 European Leukemia Net (ELN) response criteria
was adopted to deﬁne chronic, accelerated, blastic phases and
to assess the response [12]. An optimal response to imatinib is
deﬁned by CHR at 3 months, BCR-ABL: ABL < 10% at
6 months, BCR-ABL: ABL < 1% at 12 months and MMR
at 18 months. Failure is deﬁned by incomplete HR at
3 months, no CHR at 6 months, BCR-ABL: ABL > 10% at
12 months, and BCR-ABL: ABL > 1% at 18 months. In any
other situation, the response is deﬁned suboptimal.
Adverse events were assessed according to common
terminology criteria for adverse effects (CTCAE) version 3.0
[13].Statistical analysis
Descriptive statistical analysis was carried out to assess the
patients’ demographics and clinical characteristics. Patients
were divided into 2 groups according to prior hydroxyurea
administration or imatinib interruption. The comparison
between the 2 groups and the response was assessed using
the Chi-square test. Survival plots were drawn using the
Kaplan–Meier method [14]. The log-rank test was used to
assess the survival difference between groups. Univariate
analysis using Cox regression module was performed to test
the power of relation between variables and survival.
Differences were considered signiﬁcant if p value was less than
0.05 [15]. All analyses were performed using SPSS statistical
software (version 20.0).
Progression free survival (PFS) was deﬁned as the time
from the start of imatinib to the onset of an accelerated or
blastic phase, discontinuation of imatinib due to failure, sub-
optimal response or death.Results
During the study period, 60 patients were included. Thirty-
three patients (55%) received imatinib upfront, while 27
(45%) received imatinib post hydroxyurea. Of the latter group,
patients were shifted to imatinib as soon as the drug was avail-
able through the ministry of health. Hydroxyurea was used
Table 1 Baseline characteristics of whole group patients
included in the study.
Characteristics n (%)
Age (years) Median 46
Range 18–86
>60 years 10(17)
Gender Male 30(50)
Female 30(50)
EUTOS score Low 45(75)
High 15(25)
White cell count (109/L) Median 150
Range 29.8–500
Hemoglobin (g/dl) Median 10
Range 6.4–12.6
Platelet count (109/L) Median 271
Range 93–797
 EUTOS: European Treatment and Outcome Study for CML.
 Gram/deciliter.
Table 2 Response to imatinib therapy in whole group patients
included in this study according to prior hydroxyurea.
Variable Imatinib
upfront n:33
Imatinib post
hydroxyurea n:27
P
value
Complete
hematologic
response
31 (94%) 24 (89%) 0.234
Major molecular
response
19 (57.5%) 15 (55.5%) 0.757
Complete molecular
response
9 (27%) 6 (22%) 0.462
Table 3 Response to imatinib therapy in whole group patients
included in this study according to drug interruption.
Variable No
interruption
(n:30)
Interruption
(n: 30)
P value
Complete hematologic
response
38 (95%) 17 (85%) 0.348
Major molecular
response
28(70%) 6(30%) <0.001
Complete molecular
response
13(32%) 0(0%) <0.001
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60 months prior to imatinib.
The median age of the patients was 46 years, with no gender
predominance (Male:Female ratio 1:1). The majority of the
cases had low risk (75%) according to EUTOS scoring system.
Baseline patients’ characteristics are summarized in Table 1.
At a median follow up of 22 months, the rate of CHR,
MMR and CMR was not statistically different in the group
who had imatinib upfront compared to those who had hydrox-
yurea, Table 2. By comparing those who were regular on ima-
tinib to those who had interruption, there was a statistically
signiﬁcant difference observed in both MMR (p< 0.001)
and CMR (p< 0.001) while CHR was similar (p= 0.348)
(Table 3).
Imatinib dose and safety
All patients started on imatinib 400 mg daily. The dose was
reduced to 300 mg/day in 7 patients (11.6%) due to recurrent
neutropenia or thrombocytopenia.
The median treatment duration was 14.6 months (range:
1–64). Imatinib was not given regularly in 50% of patients
due to ﬁnancial and logistic reasons, with median treatment
interruption of 21 days (range 7–50 days), with most of the
treatment delay encountered after the ﬁrst year of therapy.The predominant grade 1 and 2 hematological toxicity of
imatinib included neutropenia (27%), followed by anemia
(24%) and thrombocytopenia (15%). None of the patients
developed grade 3 or 4 hematological adverse events.
The most commonly reported non hematological adverse
event of imatinib included peripheral edema (31%), muscle
cramps (30%), fatigue (26%), and skin rash (10%), these
events were mostly grade 1 or 2 toxicity. Only one patient dis-
continued imatinib due to grade 3 arthralgia.
Survival analysis
The median PFS was 30.3 months (95% CI 24.3–36.3) (Fig. 1).
No statistically signiﬁcant difference was observed in PFS
according to EUTOS score (p= 0.334) (Fig. 2) or duration
of prior hydroxyurea administration (p= 0.224), (Fig. 3).
Patients regular on imatinib had longer PFS compared to
those who had periods of drug interruption (p= 0.049),
(Fig. 4 and Table 4).
Discussion
Philadelphia-positive, BCR-ABL1-positive CML is a simple
model of cancer driven by a single, speciﬁc, chromosome trans-
location, the t(9;22)(q22;q11), that leads to the formation of a
new, hybrid, leukemia-speciﬁc gene (BCR-ABL1) that codes
for a unique protein that drives the leukemic transformation
of hematopoietic stem cells. This makes CML an ideal model
for true targeted therapy [6].
In the current analysis, we reviewed the response and safety
of imatinib in our institute from January 2010 to November
2013. Before 2009, hydroxyurea was the main treatment line
for our patients with chronic phase CML, while interferon
alpha was used only for few patients due to the cost and side
effects.
The median age of our patients was 46 years. CML has a
slight male predominance [3,4], however, in the present study,
cases were distributed equally in both genders. Various scoring
systems have been devised in an attempt to predict disease out-
come, Sokal [16] and Euro (Hasford) [17] scores were devel-
oped prior to the discovery of imatinib, the EUTOS score
was developed and validated using data from 2060 patients
enrolled in prospective studies of imatinib [18]. In our analysis,
the majority of the cases ranked in the low risk group (75%).
In the major studies testing the efﬁcacy of imatinib 400 mg
daily in CML, the proportion of patients who achieved MMR
after 1 year of therapy ranged from 18% to 58% [19–25]. In a
Figure 2 Progression-free survival of the whole group patients included in this study according to EUTOS score.
Figure 1 Progression-free survival of the whole group patients included in this study.
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MMR at 18 months was achieved by 98.2%, and 51% respec-
tively [26]. In the present study, the rate of CHR and MMR
according to prior hydroxyurea or imatinib interruption was
91.6%, 56.6% respectively, CMR was 25% and 21.6% for
the patients stratiﬁed according to prior hydroxyurea and ima-
tinib interruption respectively. These ﬁgures are somewhat
lower than those of the international studies while similar to
the Egyptian one. The importance to maintain patients regu-
larly on imatinib was addressed in SPIRIT2 study, in whichtreatment interruption or dose reduction of imatinib or dasa-
tinib in newly diagnosed CML within ﬁrst 3 months was asso-
ciated with poorer molecular response at 3 and 12 months [27].
In our analysis, the MMR and CMR were statistically signiﬁ-
cant in favor of those who were receiving imatinib regularly.
In the published literature, PFS ranged between 83% and
94% and the number of patients still receiving initial imatinib
treatment was reported at 63% to 79% after 3 to 5 years
[28–37]. In our analysis, the PFS, and the percentage of those
who are still receiving imatinib, were inferior to the previously
Figure 3 Progression free survival according to duration of hydroxyurea therapy (<1 month versus >1 month).
Figure 4 Progression-free survival according to imatinib interruption.
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countries [38,39]. These results could be attributed to small
number of patients, retrospective nature of the study, and
irregular intake of imatinib.
In our study, there was no signiﬁcant difference in response
or PFS in the group of patients who received imatinib as the
initial treatment compared to those who received it after
hydroxyurea. On the contrary, there was a signiﬁcant lower
median PFS in patients with irregular administration of ima-
tinib compared to those who were regular on the drug. Thus,a short delay in starting imatinib is better than starting earlier
then had to interrupt the drug due to unavailability.
In the present analysis, half of the cases received imatinib
irregularly. The cost of imatinib is high, particularly because
treatment needs to be continued for life. In Egypt, imatinib
is provided through the ministry of health, and similar to other
developing countries; we have ﬁnancial problems to maintain
our patients on imatinib continuously without interruption.
The introduction of imatinib was celebrated as the begin-
ning of a new era of cancer treatment, in which therapy was
Table 4 Univariate analysis for factors affecting Progression Free Survival.
Variable Number of cases 2 years PFS (%) P value HR 95% CI
Prior hydroxyurea No 33 65 0.673 1.21 0.49–2.96
Yes 27 62
Imatinib interruption No 30 70 0.049 2.38 1.01–5.99
Yes 30 60
EUTOS score High 15 50 0.360 1.61 0.58–4.48
Low 45 70
HR: hazard ratio; EUTOS: European Treatment and Outcome Study.
74 W.A. Edesa, R.R. Abdel-malekﬁnally nontoxic, safe and well-tolerated [40]. After more than
10 years, these promises were largely fulﬁlled because the side
effects of imatinib are usually mild, with only rare severe, life
threatening complications [41]. Overall, imatinib was tolerable
in our patients, most of the adverse events were manageable,
only one patient stopped therapy due to grade 3 arthralgia.
In conclusion, duration of prior hydroxyurea had no
impact on response or PFS, while patients regular on imatinib
had statistically signiﬁcant difference of MMR, CMR and
PFS, compared to those who had periods of drug interruption.
Thus, we need more governmental support to supply the drug
without interruption to improve treatment outcome for our
CML patients.
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